Table 3:
Sensitivity analyses to evaluate the associations between HBV infection and selected cancers
| Cancer | No. with HBV infection** (in the primary analyses) | Excluding HCV and HIV infected individuals | Strict HBV* definition | Excluding HCV and HIV-infected individuals plus strict HBV* definition | |||
|---|---|---|---|---|---|---|---|
|
| |||||||
| No. with HBV infection** | aOR† (95% CI) | No. with HBV infection* | aOR† (95% CI) | No. with HBV infection* | aOR† (95% CI) | ||
| Stomach | 288 | 211 | 1.20 (1.01 - 1.41) | 129 | 1.11 (0.90 - 1.38) | 88 | 1.16 (0.90 - 1.50) |
| Anus | 35 | 24 | 1.63 (1.08 - 1.46) | 18 | 1.85 (1.15 - 3.00) | < 11 | 1.64 (0.86 - 3.12) |
| Liver | 1,658 | 421 | 5.37 (4.69 - 6.14) | 1,025 | 12.4 (10.9 - 14.0) | 277 | 8.07 (6.73 - 9.66) |
| Intrahepatic bile duct | 35 | 19 | 1.28 (0.80 - 2.05) | 24 | 2.48 (1.63 - 3.77) | < 11 | 1.62 (0.85 - 3.06) |
| Other biliary tract | 34 | 20 | 1.25 (0.80 - 1.97) | 15 | 1.41 (0.84 - 2.39) | < 11 | 0.89 (0.39 - 2.02) |
| Female breast | 781 | 573 | 0.88 (0.76 - 1.02) | 296 | 0.73 (0.60 - 0.88) | 185 | 0.71 (0.56 - 0.91) |
| Prostate | 1,254 | 879 | 0.81 (0.71 - 0.93) | 505 | 0.70 (0.60 - 0.83) | 319 | 0.68 (0.55 - 0.83) |
| MDS | 189 | 117 | 1.11 (0.91 - 1.37) | 94 | 1.31 (1.03 - 1.66) | 46 | 1.01 (0.73 - 1.41) |
| DLBCL | 184 | 121 | 1.14 (0.93 - 1.39) | 98 | 1.46 (1.16 - 1.83) | 53 | 1.23 (0.91 - 1.67) |
| CLL/SLL | 88 | 61 | 0.76 (0.58 - 0.99) | 37 | 0.71 (0.51 - 1.00) | 22 | 0.66 (0.43 - 1.02) |
| Nasopharynx | 21 | 16 | 2.20 (1.32 - 3.67) | < 11 | 1.84 (0.94 - 3.61) | < 11 | 1.93 (0.85 - 4.41) |
| Other gastrointestinal sites | 45 | 30 | 1.31 (0.90 - 1.91) | 16 | 1.08 (0.65 - 1.78) | < 11 | 0.96 (0.49 - 1.88) |
Abbreviations: aOR, adjusted odds ratio; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B cell lymphoma; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus
At least 1 MEDPAR, or 2 NCH or OUTPT claims at least 30 days apart, excluding 12 months before the cancer diagnosis/control selection date
At least 1 MEDPAR, NCH, or OUTPT claim, excluding 12 months before the cancer diagnosis/control selection date
Odds ratios assess the association of HBV with the specified cancer and were adjusted for age categories (66-69, 70-74, 75-79, 80-84, ≥85 years), sex, race/ethnicity, calendar year of cancer diagnosis/control selection (1993-2000, 2001-2004, 2005-2008, 2009-2013), average number of physician claims per year (< 2.67, 2.67-5.69, 5.70-10.24, ≥10.25), and smoking status (never/ever)